

Mahmoud Mahmoudian Ph.D. FRS Director
Caravan Biologix

Dr. Mahmoudian’s career spans over 3 decades of operating, company building, fund raising and investment expertise driving growth strategies to develop and commercialize the next generation artificial intelligence-based vaccines, RNA, genetic and precision medicines.
He was recruited to Cobro Ventures as Partner leading venture creation and biotech investments operating across its portfolio as President, CEO (MANA Therapeutic) and Chief Business Officer (AI Proteins, Dynamic Cell Therapies).
Prior to this position, Dr. Mahmoudian was Senior Vice President, Head of Global Oncology External Innovation Hub at Sumitomo Pharma establishing a corporate venture fund as an early-stage investor. As Chief Science Scout, he led venture investments, business development and external partnerships with academia, syndicating with venture capital to develop new biology, technologies and treatments in cancer including a $3B M&A with Roivant.
Earlier in his career, Dr. Mahmoudian led global drug development and innovation teams at Merck, GlaxoSmithKline and Ferring with 10 FDA approvals ($15B sales) including Adstiladrin®, the first gene therapy approved for bladder cancer and Rebyota®, the first microbiome-based treatment approved for recurring C. difficile infections.
Dr. Mahmoudian earned his Doctor of Philosophy (PhD) and Master of Science (MSc) from the Imperial College London. He is on the Board of Directors of BioEclipse Therapeutics, and Contera Pharma, a Fellow of the Royal Society (FRS), and an Executive in Residence at Columbia and Princeton Universities.